Transgenic animals with reduced major urinary protein production
OwnerMartin John Evans, Fiona Catherine Mansergh +2inventors
InventorsMartin John Evans, Fiona Catherine Mansergh, Jane Louise Hurst, Robert Jeffrey Beynon
Life of this patent
Estimating the term…
Abstract
The present invention relates to a transgenic animal having substantially reduced major urinary protein (uMUP) production. The present invention also relates to methods of producing such animals, and to the uses of such animals.
Claims37
A transgenic animal from whose genome a uMUP complex has been inactivated or deleted, wherein said inactivation or deletion substantially reduces the production of uMUPs.
A method of producing a transgenic animal which has substantially reduced uMUP production, comprising these steps of:
- a) providing embryonic stem cells from the relevant animal species comprising an intact uMUP complex;
- b) providing one or more targeting vectors capable of inactivating the uMUP complex,
- c) introducing the one or more vectors into the embryonic stem cells and selecting for cells with an inactivated uMUP complex;
- d) introducing an embryonic stem cell having an inactivated uMUP complex into a blastocyst;
- and
- e) implanting the blastocyst into the uterus of a female animal and allowing it to gestate before delivering the resulting offspring.
A method according to claim 14 or claim 151 wherein the one or more vectors delete the uMUP complex.
18 A method according to claim 14, wherein the one or more vector comprise two vectors which flank the uMUP complex
A method according to claim 18 wherein the two vector comprise LoxP regions which bring about deletion of the region by Cre-mediated recombination.
A method selecting animals produced by the methods of the invention comprising testing the animals for the inactivation of the uMUP complex.
The use of a transgenic animal having substantially reduced uMUP production in behavioral studies.
The use of a transgenic animal having substantially reduced uMUP production to establish the molecular mechanism underlying MHC associated odours.
The use of transgenic animals having substantially reduced uMUP production to identify agents which affect animal behavior.
The use of animals having substantially reduced uMUP production as hypoallergenic laboratory animals.
The use of animals having substantially reduced uMUP production as pets.
An embryonic stem cell that is heterozygous or homozygous for an inactivated uMUP complex.
A transgenic animal where the uMUP complex is flanked by LoxP sites or equivalent sites capable of recombining to delete the uMUP complex in response to the presence of a recombinase.
An embryonic stem cell wherein the uMUP complex is flanked by LoxP sites or equivalent sites capable of recombining to delete the uMUP complex in response to the presence of a recombinase.
Dependencies are inferred from the claim text.